01—Abstract
Summary
Summary of the 8-K/A filed June 16, 2026. Cited figures are marked; the original filing is the authoritative source.
Natera, Inc. (NTRA) filed this Form 8-K on June 16, 2026 under Item 5.02 to report a board change.
The Board increased the size of the full Board from eleven to twelve members and appointed Thomas Lynch as a member, both effective June 2, 2026. Dr. Lynch will serve as a Class I director with an initial term expiring at the 2028 annual meeting of stockholders, and the Board determined he is independent under Nasdaq listing standards and the Securities Act. He was appointed to the Human Capital Committee.
Dr. Lynch will receive cash and equity compensation consistent with the Company's other non-employee directors, as described in the Amended Compensation Program for Non-Employee Directors previously filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2025. His initial equity award vests as to one-third of the shares on each of June 26, 2027, 2028, and 2029. The Company also expects to enter into an Indemnification Agreement with him.
The filing states there are no family relationships between Dr. Lynch and any directors or executive officers, and no arrangement or understanding under which he was elected, and he has no material interest in related-person transactions under Item 404(a). This amendment was filed solely to add XBRL tagging omitted from the original filing and makes no changes to the disclosures.
02—Key points
Key Highlights
- Board expanded from eleven to twelve members, effective June 2, 2026
- Thomas Lynch appointed as a Class I director with a term expiring at the 2028 annual meeting
- Board determined Dr. Lynch is independent under Nasdaq listing standards
- Dr. Lynch appointed to the Human Capital Committee
- Initial equity award vests one-third each on June 26, 2027, 2028, and 2029
- Company expects to enter into an Indemnification Agreement with Dr. Lynch
- Amendment filed solely to add omitted XBRL tagging; no changes to original disclosures
03—Questions
Frequently Asked Questions
Who was appointed to Natera's Board of Directors?
Thomas Lynch was appointed as a member of the Board, effective June 2, 2026, as a Class I director with an initial term expiring at the 2028 annual meeting of stockholders.
Did the Board size change?
Yes. The Board increased the size of the full Board from eleven to twelve members, effective June 2, 2026.
What compensation will the new director receive?
Dr. Lynch will receive cash and equity compensation consistent with the Company's other non-employee directors. His initial equity award vests as to one-third of the shares on each of June 26, 2027, 2028, and 2029.
Is the new director independent and on any committees?
The Board determined Dr. Lynch qualifies as independent under the Securities Act and Nasdaq listing standards. He has been appointed to the Human Capital Committee.
Why was this filing amended?
The amendment was filed solely to add XBRL tagging that was inadvertently omitted from the original filing. It does not change any disclosures in the Form 8-K.
04—Continue